Promo !

TAK-653 (Osavampator) 2 mg – 60 tablets

Le prix initial était : $64.00.Le prix actuel est : $60.00.

TAK-653 (Osavampator, NBI-1065845) 2 mg — 60 research tablets. TAK-653 is the most clinically advanced AMPA-receptor positive allosteric modulator (PAM) in development: a non-dissociative, non-psychotomimetic glutamate-system molecule that separated from placebo on the MADRS in a placebo-controlled Phase II study in major depressive disorder, without the hallucinogenic, dissociative or addictive liabilities of NMDA antagonists. It has since entered a Phase III registrational programme under Neurocrine Biosciences, which makes it the reference tool compound for the glutamatergic side of rapid-acting antidepressant pharmacology.

 

RESEARCH USE ONLY  ·  Not for human or veterinary use. For laboratory and collector purposes only.

 

Purity
≥ 99 % (HPLC) — third-party tested, CoA on file
Form
Research tablets
Content
2 mg TAK-653 (osavampator) per tablet
Total
60 tablets per bottle (120 mg total)
Packaging
Sealed bottle with tamper-evident closure
Storage
Room temperature, dry, protected from light
Molecular formula
C₁₉H₂₃N₃O₃S
Molecular weight
≈ 373.47 g·mol⁻¹
IUPAC name
9-(4-cyclohexyloxyphenyl)-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide
CAS number
1358751-06-0
Synonyms
TAK-653; Osavampator; NBI-1065845

 

Research Overview

TAK-653 is a selective, non-desensitizing positive allosteric modulator of the AMPA subtype of ionotropic glutamate receptors, the principal mediator of fast excitatory neurotransmission in the mammalian brain [1]. Unlike older AMPA-PAMs, it has been engineered to lack the convulsant liability of high-efficacy ampakines while retaining robust enhancement of synaptic AMPA signaling in physiologically relevant ranges. In the placebo-controlled Phase II SAVITRI study (183 adults with major depressive disorder and an inadequate response to their current antidepressant), a low-dose and a high-dose arm were given once daily for eight weeks alongside ongoing treatment; the low-dose arm (reported as 1 mg) separated significantly from placebo on the MADRS at Day 28 and Day 56, while the high-dose arm (reported as 3 mg) did not [2]. AMPA receptors themselves can now be imaged in the living human brain with the [¹¹C]K-2 PET probe, giving the field a direct translational readout for AMPA-targeted research [3]. The molecule has since advanced under Neurocrine Biosciences as osavampator (NBI-1065845) into a Phase III registrational programme, and represents the first credible non-NMDA, non-dissociative, rapid-acting antidepressant chemotype.

 

Primary Research Areas

  • AMPA-receptor positive allosteric modulation — the most clinically advanced selective AMPA-PAM available as a research tool; the reference compound for non-desensitizing AMPA signaling research [1].
  • Rapid-acting antidepressant mechanisms — Phase II evidence as an adjunctive treatment in major depressive disorder with inadequate antidepressant response, with no dissociative effects reported [2].
  • Glutamatergic synaptic plasticity — studied for LTP enhancement, BDNF release and synaptogenesis — the proposed mechanism of rapid antidepressant action [1].
  • Cognitive and procognitive research — evaluated in working-memory and executive-function paradigms in healthy human and rodent cohorts [1].
  • Translational PET pharmacology — studied alongside AMPA-receptor PET imaging ([¹¹C]K-2), which quantifies AMPA receptors in the living human brain [3].

 

References

  1. Hara H, Suzuki A, Kunugi A, Tajima Y, Yamada R, Kimura H. TAK-653, an AMPA receptor potentiator with minimal agonistic activity, produces an antidepressant-like effect with a favorable safety profile in rats. Pharmacol Biochem Behav. 2021;211:173289.
  2. Neurocrine Biosciences. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of NBI-1065845 (osavampator) in adults with major depressive disorder (SAVITRI). ClinicalTrials.gov: NCT05203341.
  3. Miyazaki T, Nakajima W, Hatano M, et al. Visualization of AMPA receptors in living human brain with positron emission tomography. Nat Med. 2020;26(2):281–288.
TAK-653 (also known as Osavampator or NBI-1065845) is an investigational, central nervous system-penetrant AMPA receptor positive allosteric modulator (PAM) being developed by Takeda Pharmaceuticals and Neurocrine Biosciences as a potential treatment for treatment-resistant depression (TRD) and major depressive disorder (MDD). [1, 2, 3, 4]
How It Works
  • AMPA Receptor Modulation: Unlike traditional direct agonists that can overstimulate receptors or cause seizures, TAK-653 selectively amplifies glutamate signals at AMPA receptors with minimal direct agonism. [1, 2, 3]
  • Synaptic Plasticity: It enhances synaptic transmission, promotes the release of brain-derived neurotrophic factor (BDNF), and increases cortical excitability. [1, 2, 3]
  • Dopamine-Sparing: Unlike standard stimulants or traditional antidepressants, it does not rely heavily on dopamine or serotonin pathways. [1, 2]

Research and Development Status

  • Clinical Trials: Studied in human clinical trials (such as NCT03312894) for efficacy and safety in patients with treatment-resistant depression. [1]
  • Ketamine Comparison: Preclinical and clinical models suggest it may offer rapid antidepressant-like effects similar to ketamine, but with a lower risk of hyperlocomotor response, psychotomimetic side effects, or abuse potential. [1, 2, 3]
  • Partnership: Originally discovered by Takeda Pharmaceuticals, development is co-advanced with Neurocrine Biosciences (which holds global rights outside Japan). [1]

Why Limitless Biochem Shop?

Limitless BioChem is a trusted supplier of research compounds. Our products meet strict quality standards and are compliant with EU requirements. We focus on the safe and reliable supply of peptides and pure compounds intended exclusively for research or collector purposes.

This product is not intended for human or veterinary use. It is for collection or research purposes only. It cannot be used as food, dietary supplement or medicine! The information provided in the text on this page is for educational purposes only and does not constitute medical or other advice.

Avis

Il n’y a pas encore d’avis.

Soyez le premier à laisser votre avis sur “TAK-653 (Osavampator) 2 mg – 60 tablets”

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont indiqués avec *

Panier

Save to list